Polsinelli Counsels Avanos Medical in Qualifying for Separate Payment Under NOPAIN Act

A team of Polsinelli’s FDA and Medicare regulatory attorneys and public policy advisors recently counseled Avanos Medical, a medical technology company focused on delivering clinically superior medical device solutions, in meeting qualifying requirements for separate payment for two of its devices under the NOPAIN ACT.

The NOPAIN Act aims to increase patient access to non-opioid drugs and devices used to manage pain in Hospital Outpatient and Ambulatory Surgical Center settings by providing additional, separate Medicare reimbursement for qualifying non-opioid items.

The Centers for Medicare and Medicaid Services confirmed that both the Avanos ON-Q elastomeric infusion pump and the Avanos ambIT disposable electronic infusion pump meet qualifying requirements, marking a significant milestone as both medical devices become eligible for separate payment for the first time under the NOPAIN Act.

More information about Avanos and its devices that qualify for separate payment under the NOPAIN Act can be found here.

Food and Drug Practice Vice Chair Michael M. Gaba led the team advising and advocating for Avanos over the past several years, that included Shareholder Steve Stranne, MD and Senior Policy Advisors Shelagh Foster and Tim Perrin.